NetworkNewsBreaks

TuesdayMar 16, 2021 1:39 pm

NetworkNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Completes Enrollment in Upcoming Phase 2b Clinical Trial of Cystic Fibrosis Treatment

AzurRx BioPharma (NASDAQ: AZRX), a clinical-stage biopharmaceutical company specializing in the development of targeted, nonsystemic therapies for gastrointestinal (“GI”) diseases, has announced the completion of enrollment for its phase 2b OPTION 2 clinical trial to investigate MS1819 in cystic fibrosis (“CF”) patients with exocrine pancreatic insufficiency (“EPI”). According to the announcement, the company enrolled 30 CF patients for the study, which is anticipated to return top line data by the end of Q1 2021. The upcoming phase 2b, multicenter study will investigate the safety, tolerability and efficacy of MS1819 in a head-to-head comparison against the current porcine enzyme replacement therapy…

Continue Reading

TuesdayMar 16, 2021 1:22 pm

NetworkNewsBreaks – Sanwire Corp. (SNWR) Subsidiary Announces Partnership with Meridian Gates Entertainment

Sanwire (OTC: SNWR), a diversified company with a focus on technologies for the entertainment industry, has announced that the Meridian Gates Entertainment label has joined Intercept Music Inc.’s artist incubation program. Intercept Music is a wholly owned subsidiary of Sanwire, and Meridian Gates Entertainment is a production house and record label based in Miami, Florida. Top acts handled by Meridian Gates include Maxi Priest, Bunny Wailer, The Wailers and Buju Banton. Many of Meridian’s artists will be participating in the label incubator program as well as Intercept PLUS; the announcement noted that two-time Grammy nominee Maxi Priest would be the first act…

Continue Reading

TuesdayMar 16, 2021 1:03 pm

NetworkNewsBreaks – Healthtech Solutions Inc. (HLTT) Announces Incorporation of New RevHeart Inc. Subsidiary

Healthtech Solutions (OTC: HLTT), parent company of Medi-Scan Inc., today announced the incorporation of a new subsidiary called RevHeart Inc. According to the update, the new subsidiary will conduct further research into finding a treatment for COVID-related heart muscle injury. In direct support of the company’s ongoing efforts, RevHeart’s research team is developing the ability to identify and track myocardial deformities to enable implementation of a therapy to ameliorate and potentially repair myocardial damage. Based on positive results to date, RevHeart has filed a provisional patent application with the U.S. Patent and Trademark Office titled, "System, Method and Apparatus for…

Continue Reading

TuesdayMar 16, 2021 12:46 pm

NetworkNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Announces Continued Manufacturing Progress

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive procedures, today announced continued progress towards commercial-stage manufacturing capability with Lighthouse Imaging. Prior to selection of Lighthouse as its contract manufacturer for the i/Blue Imaging System(TM) in October 2020, Imagin received multiple fully functional feasibility units from its original design partner, Optel Inc. Lighthouse’s development program has since focused on further refining the design to support Imagin’s submissions to the U.S. Food and Drug Administration, as well as to ensure final device performance, compliance with all…

Continue Reading

TuesdayMar 16, 2021 12:22 pm

NetworkNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Participation Schedule for Upcoming March Investor Conferences

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced that its Chief Executive Officer, Shawn Singh, will participate in two investor conferences in March. For the Maxim Group and M-Vest’s Inaugural Emerging Growth Virtual Conference taking place on March 17-19, 2021, Singh will deliver a corporate presentation and participate in a fireside chat, scheduled to begin at 1 p.m. ET on Friday, March 19. In addition, Singh will deliver a corporate presentation at the Benzinga Biotech…

Continue Reading

TuesdayMar 16, 2021 12:03 pm

NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) to Present at Oppenheimer Health Care Conference

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced that its Chief Executive Officer, Doug Drysdale, will be presenting a business and pipeline update at the Oppenheimer 31st Annual Healthcare Conference. Drysdale’s presentation is scheduled to begin at 11:20 a.m. Eastern Time on Thursday, March 18, 2021. Interested parties should visit https://nnw.fm/fTQZw to register for the event. The presentation will be webcast live at the aforementioned time and available for seven days thereafter via the above link. To view the full press release, visit https://nnw.fm/bvdnP About Cybin Inc. Cybin is a leading biotechnology company…

Continue Reading

TuesdayMar 16, 2021 11:15 am

NetworkNewsBreaks – Uranium Energy Corp. (NYSE American: UEC) Announces Balance Sheet Update, Physical Uranium Initiative

Uranium Energy (NYSE American: UEC), a Corpus Christi, Texas-based uranium mining and exploration company, today announced, in accordance with NYSE American requirements, the filing of its quarterly report on Form 10-Q for the six months ended January 31, 2021 with the U.S. Securities and Exchange Commission (the "SEC"). The Form 10-Q filing, which includes UEC’s condensed consolidated financial statements, related notes and management's discussion and analysis, is available for viewing on the SEC's website or the company’s website. "With $65.8 million in cash and equity holdings, UEC has the balance sheet strength to lead U.S. uranium production higher at the…

Continue Reading

TuesdayMar 16, 2021 10:51 am

NetworkNewsBreaks – Trxade Group Inc. (NASDAQ: MEDS) Schedules Call, Will Release Q4 and FY 2020 Financial Results

Trxade Group (NASDAQ: MEDS), a health-services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the United States, has announced that it will report Q4 and FY 2020 financial results. MEDS will release the numbers, which are for the fourth quarter and fiscal year ended Dec. 31, 2020, after market close on March 29, 2021. As part of the reporting strategy, MEDS management will host a conference call. The call is scheduled for 5 p.m. ET on Monday, March 29, 2021. During the scheduled event, Trxade Group execs will discuss the…

Continue Reading

TuesdayMar 16, 2021 10:27 am

NetworkNewsBreaks – Clean Power Capital Corp. (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF) Releases AGMS Results, Names New CEO

Clean Power Capital (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF) held an annual general and special meeting on Monday, March 15, 2021. The company has announced that all matters outlined in the notice of meeting and information circular, which was sent to all shareholders, were approved and passed. Included in those items was the approval and ratification of MOTNF’s amended and restated investment policy; the policy will now include the renewable energy sector as an area of investment focus for the company. Shareholders also elected and established and named a four-member board of directors. Board members will be Johannes (Theo) van…

Continue Reading

TuesdayMar 16, 2021 9:50 am

NetworkNewsBreaks – Assertio Holdings Inc. (NASDAQ: ASRT) Closes $14M, $34.3M Registered Direct Offerings

Assertio Holdings (NASDAQ: ASRT), a commercial-stage pharmaceutical company, has announced the closing of two registered direct offerings — both completed last month. On Feb. 9, 2021, Assertio closed sales of 22,600,000 shares of common stock; the shares were sold to certain institutional investors at $0.62 per share. The closing of this first registered direct offering totaled $14 million in gross proceeds for the company. The company closed on its second registered direct offering on Feb. 12, 2021. That offering was comprised of 35,000,000 shares of common stock, again sold to certain institutional investors. Those shares were purchased at $0.98 per…

Continue Reading